AstraZeneca's already dominant Lynparza lines up for early breast cancer with new trial win



AstraZeneca could be looking at earlier use of its PARP inhibitor Lynparza in breast cancer, thanks to a new clinical trial win.

When used after surgical removal of tumors, Lynparza topped placebo at fending off invasive disease and preventing death among patients with BRCA-mutated, high-risk, HER2-negative early breast cancer, AstraZeneca said Wednesday.

An independent data monitoring committee said the phase 3 OlympiA trial had crossed the superiority bar for that primary endpoint and recommended investigators start analyzing specific data. And that means AstraZeneca could report the so-called "invasive disease-free survival" data earlier than expected, the company said.

AZ said last week that it was expecting to take the OlympiA data to regulators in the second half of this year.

The trial will continue to follow patients for secondary endpoints, such as Lynparza’s ability to prevent distant disease recurrence and—more importantly—whether it can help patients live longer.

In BRCA-mutated HER2-negative breast cancer, Lynparza’s already approved to treat patients with metastatic disease who've previously received chemotherapy—either before or after surgery—as treatment for active disease.

If Lynparza eventually gets an FDA go-ahead based on OlympiA, it would be able to help patients with earlier-stage tumors in patients after surgery—otherwise known as the adjuvant setting.

Lynparza, which AstraZeneca markets in collaboration with Merck & Co., is so far the market leader in the PARP inhibitor class, mainly thanks to its larger ovarian cancer indications.

In 2020, sales of Lynparza jumped 48% year over year to reach $1.78 billion. GlaxoSmithKline’s Zejula, Clovis Oncology’s Rubraca and Pfizer’s Talzenna came nowhere near Lynparza in terms of sales.

Aside from adjuvant breast cancer, AZ this year also expects to read out data from the phase 3 PROpel trial, which tests Lynparza plus Johnson & Johnson’s Zytiga against solo Zytiga in previously untreated metastatic castration-resistant prostate cancer.

Source:https://www.fiercepharma.com/marketing/astrazeneca-s-lynparza-up-for-early-post-surgery-use-breast-cancer-new-trial-win

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more